Cogent Biosciences Shares Double On Tumor Drug Positive Trial Results

Dow Jones

2025/11/10

By Nicholas G. Miller

Shares of Cogent Biosciences soared after the company reported positive trial data for its treatment of Gastrointestinal Stromal Tumors that surpassed its expectations.

The stock more than doubled in premarket trading to $30.97 Monday after closing Friday up 90% this year.

In a phase three trial, the company's treatment combining bezuclastinib with sunitinib showed 16.5 months median progression free survival compared to 9.2 months for sunitinib monotherapy. The safety profile was also well tolerated.

"The bezuclastinib combination is poised to become the new standard of care for treatment of second-line GIST patients," said Cogent Chief Executive Andrew Robbins.

The company said it planned to submit a new drug application for bezuclastinib in the first half of next year.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

November 10, 2025 09:08 ET (14:08 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2582687216"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582687216\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582687216?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 22:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582687216","market":"sh","top_or_hot":-1,"title":"Cogent Biosciences Shares Double On Tumor Drug Positive Trial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/COGT\">Cogent Biosciences</a> soared after the company reported positive trial data for its treatment of Gastrointestinal Stromal Tumors that surpassed its expectations. \n</p>\n<p>\n  The stock more than doubled in premarket trading to $30.97 Monday after closing Friday up 90% this year. \n</p>\n<p>\n  In a phase three trial, the company's treatment combining bezuclastinib with sunitinib showed 16.5 months median progression free survival compared to 9.2 months for sunitinib monotherapy. The safety profile was also well tolerated. \n</p>\n<p>\n  \"The bezuclastinib combination is poised to become the new standard of care for treatment of second-line GIST patients,\" said Cogent Chief Executive Andrew Robbins. \n</p>\n<p>\n  The company said it planned to submit a new drug application for bezuclastinib in the first half of next year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 10, 2025 09:08 ET (14:08 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cogent Biosciences Shares Double On Tumor Drug Positive Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCogent Biosciences Shares Double On Tumor Drug Positive Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-10 22:08</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/COGT\">Cogent Biosciences</a> soared after the company reported positive trial data for its treatment of Gastrointestinal Stromal Tumors that surpassed its expectations. \n</p>\n<p>\n  The stock more than doubled in premarket trading to $30.97 Monday after closing Friday up 90% this year. \n</p>\n<p>\n  In a phase three trial, the company's treatment combining bezuclastinib with sunitinib showed 16.5 months median progression free survival compared to 9.2 months for sunitinib monotherapy. The safety profile was also well tolerated. \n</p>\n<p>\n  \"The bezuclastinib combination is poised to become the new standard of care for treatment of second-line GIST patients,\" said Cogent Chief Executive Andrew Robbins. \n</p>\n<p>\n  The company said it planned to submit a new drug application for bezuclastinib in the first half of next year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 10, 2025 09:08 ET (14:08 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2582687216","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582687216","pubTimestamp":1762783680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Cogent Biosciences soared after the company reported positive trial data for its treatment of Gastrointestinal Stromal Tumors that surpassed its expectations.The stock more than doubled in premarket trading to $30.97 Monday after closing Friday up 90% this year.In a phase three trial, the company's treatment combining bezuclastinib with sunitinib showed 16.5 months median progression free survival compared to 9.2 months for sunitinib monotherapy. The safety profile was also well tolerated.\"The bezuclastinib combination is poised to become the new standard of care for treatment of second-line GIST patients,\" said Cogent Chief Executive Andrew Robbins.The company said it planned to submit a new drug application for bezuclastinib in the first half of next year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","CCOI":"Cogent Communications Group","BK4139":"生物科技","COGT":"Cogent Biosciences, Inc.","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","BK4532":"文艺复兴科技持仓","BK4089":"非传统电信运营商","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC"},"translate_title":"Cogent Biosciences股价因肿瘤药物试验结果呈阳性而翻倍","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COGT":0.9,"CCOI":1.5},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  Shares of Cogent Biosciences soared after the company reported positive trial data for its treatment of Gastrointestinal Stromal Tumors that surpassed its expectations. \n\n\n  The stock more than doubled in premarket trading to $30.97 Monday after closing Friday up 90% this year. \n\n\n  In a phase three trial, the company's treatment combining bezuclastinib with sunitinib showed 16.5 months median progression free survival compared to 9.2 months for sunitinib monotherapy. The safety profile was also well tolerated. \n\n\n  \"The bezuclastinib combination is poised to become the new standard of care for treatment of second-line GIST patients,\" said Cogent Chief Executive Andrew Robbins. \n\n\n  The company said it planned to submit a new drug application for bezuclastinib in the first half of next year. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 09:08 ET (14:08 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}